DCI improves diabetic encephalopathy by modulating the BDNF/NF-κB/GSK-3β pathway

Area of Science:

• Neuroscience
• Endocrinology
• Pharmacology

Background:

• Diabetic encephalopathy (DE) causes cognitive decline and brain changes linked to diabetes.
• Current treatments for DE are limited, highlighting the need for novel therapeutic approaches.
• D-chiral inositol (DCI), a dietary compound, exhibits potential hypoglycemic and anti-inflammatory properties, but its effects on DE remain unexplored.

Purpose of the Study:

• To investigate the therapeutic potential of D-chiral inositol (DCI) in a mouse model of diabetic encephalopathy (DE).
• To elucidate the underlying molecular mechanisms by which DCI may alleviate DE-associated neuropathology and cognitive deficits.

Main Methods:

• Male db/db mice, a model for type 2 diabetes and DE, were treated with DCI (35 and 70 mg/kg/day) for 8 weeks.
• Cognitive function was assessed using the Morris water maze test.
• Hippocampal and cortical tissues were analyzed for pathological changes (HE and Nissl staining) and molecular alterations (qRT-PCR, immunohistochemistry, Western blotting) related to synaptic function, inflammation, apoptosis, and neurofibrillary tangles.

Main Results:

• DCI treatment significantly improved learning and memory in db/db mice.
• Histological analysis revealed reduced neuronal loss and pyknosis in the hippocampus and cortex of DCI-treated mice.
• DCI normalized synaptic protein levels (PSD95, SYN) and modulated inflammatory and apoptotic markers.
• Molecular analysis indicated that DCI increased BDNF, IκB-α, and p-GSK-3β (Ser9) expression while decreasing NF-κB p65, p-GSK3 (Y216+Y279), P-Tau (Thr231), and P-Tau (Ser396).

Conclusions:

• D-chiral inositol (DCI) demonstrates neuroprotective effects and cognitive benefits in a mouse model of diabetic encephalopathy (DE).
• DCI appears to exert its therapeutic effects by modulating the BDNF/NF-κB/GSK-3β signaling pathway.
• These findings suggest DCI holds promise as a potential therapeutic agent for managing diabetic encephalopathy.